Patient Selection and the Case for Earlier Referral

This segment explores why patients with lower disease burden and fewer prior lines of therapy tend to experience better outcomes, and what that means for clinical decision-making. The faculty examine data suggesting that patient selection, rather than differences in the therapy itself, largely explains why earlier-line patients respond at higher rates. Comparing treatment patterns across regions, they illustrate how outcomes converge once prior therapy exposure is accounted for, reinforcing that this therapy is appropriate to consider after progression on any checkpoint inhibitor-based treatment. The central message is that earlier intervention improves the probability of success. The experts describe thinking in terms of giving patients as many meaningful treatment opportunities as possible, and controlling the sequence of therapies rather than allowing the disease to close the window. They emphasize meeting patients early, partnering closely with referring physicians, and avoiding the exhaustion of every prior option before considering cellular therapy.